Whole blood treatment cartridge

- Qualigen Inc.
Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description

FIG. 1 is a front, top, and side perspective view of a whole blood treatment cartridge;

FIG. 2 is a top plan view thereof; the bottom plan view, front plan view, and back plan view being identical; and,

FIG. 3 is a side plan view thereof; the opposite side being a mirror image.

Claims

The ornamental design for a whole blood treatment cartridge, as shown and described.

Referenced Cited
U.S. Patent Documents
D267037 November 23, 1982 Spranger
4496458 January 29, 1985 Lee
4500309 February 19, 1985 Diederich et al.
6143510 November 7, 2000 Hoshino et al.
6277583 August 21, 2001 Krantz et al.
7214544 May 8, 2007 Poirier et al.
7226429 June 5, 2007 Tullis
D579553 October 28, 2008 Crnkovich
D600579 September 22, 2009 Wounder
7635598 December 22, 2009 Cook et al.
7754499 July 13, 2010 Poirier et al.
8288172 October 16, 2012 Ichim et al.
8317737 November 27, 2012 Hyde et al.
8709428 April 29, 2014 Shone et al.
9364601 June 14, 2016 Ichim et al.
9452219 September 27, 2016 Bates et al.
9707333 July 18, 2017 Ichim et al.
10022483 July 17, 2018 Tullis
10117933 November 6, 2018 Berry et al.
10160797 December 25, 2018 Anderson et al.
D864397 October 22, 2019 Dong
10744258 August 18, 2020 Poirier
20090114595 May 7, 2009 Wallenas et al.
20140263018 September 18, 2014 Fuhriman
20160074565 March 17, 2016 Giordano
20170095603 April 6, 2017 Cho
20190117869 April 25, 2019 Handelman et al.
20200397985 December 24, 2020 Poirier
Foreign Patent Documents
2004/064608 August 2004 WO
2007/103572 September 2007 WO
2010/030789 March 2010 WO
2011/005742 January 2011 WO
2011/112873 September 2011 WO
2015/095553 June 2015 WO
2020/176683 September 2020 WO
Other references
  • Hemoflow Low Volume Dialyzers. Presenius Medical Care. Unknown posting date. Retreived from website on Sep. 17, 2021 at: https://fmcna.com/products/disposables/dialyzers/low-volume-dialyzers/.
  • Ghirelli, C. et al., “Targeting immunosuppression for cancer therapy”, The Journal of Clinical Investigation, vol. 123, No. 6, pp. 2355-2357, (2013).
  • Focosi, D. et al., “Immunosuppressive monoclonal antibodies: current and next generation”, Clinical Microbiology and Infection, vol. 17, pp. 1759-1768, (2011).
  • Chan, A.C. et al., “Therapeutic antibodies for autoimmunity and inflammation”, Nature Reviews Immunology, vol. 10, pp. 301-316, (2010).
  • Zhang, X-B., et al., “Metal ion sensors based on DNAzymes and related DNA molecules”, Annual Review of Analytical Chemistry, vol. 4, No. 1, pp. 105-128, (2011).
  • Hotchkiss, R.S., et al., “Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach”, The Lancet Infectious Diseases, vol. 13, No. 3, pp. 260-268, (2013).
  • “Monoclonal antibodies to treat cancer”, American Cancer Society, found at www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/monoclonal-antibodies.html, pp. 1-5, Printed on Mar. 21, 2019.
  • Zhou, Q. et al., “Aptamer-containing surfaces for selective capture of CD4 expressing cells”, Langmuir, vol. 28, No. 34, p. 12544-12549, (2012).
  • Definition of “Monoclonal antibody therapy” printed from Wikipedia, the free encyclopedia, found at en.wikipedia.org/wiki/Monoclonal_antibody_therapy, Downloaded on Feb. 2, 2017.
  • Mandavilli, A. “Coronavirus can set off a “cytokine storm”. These drugs may calm it”, New York Times, found at www.nytimes.com/2020/06/11/health/coronavirus-cytokine-storm.html?searchResultPosition=1, pp. 1-5, printed on Jun. 16, 2020.
  • Product Description of “Optiflux Dialyzers”, Fresenius Renal Technologies, 2 pages, (2016).
  • Product Description of “Revaclear Dialyzer Technology”, Baxter, 4 pages, (2017).
  • Definition of “Hemodialysis” printed from Wikipedia, the free encyclopedia on Apr. 29, 2020 found at http://en.wikipedia.ora/wiki/Hemodialysis.
  • Definition of “Affinity Chromatography” printed from Wikipedia, the free encyclopedia on May 17, 2018, found at https://en.wikipedia.org/wiki/Affinity_chromatography.
  • Fischer, K-G., “Essentials of anticoagulation in hemodialysis”, Hemodialysis International, vol. 11, issue 2, pp. 178-189 (2007).
  • Frenzel, A. et al., “Expression of recombinant antibodies”, Frontiers in Immunology, vol. 4, article 217, pp. 1-20, (2013).
  • Darvin, P. et al., “Immune checkpoint inhibitors: recent progress and potential biomarkers”, Experimental & Molecular Medicine, vol. 50, article No. 165. pp. 1-11, (2018).
  • González-Rodríguez, E. et al., “Immune checkpoint inhibitors: review and management of endocrine adverse effects”, The Oncologist, vol. 21, pp. 804-816, (2016).
  • Lakhin, A.V. et al. “Aptamers: Problems, Solutions and Prospects”, Acta Naturae, vol. 5, No. 4, pp. 34-43, (2013).
  • Owens, S.M. et al., “Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction”, CNS & Neurological Disorders—Drug Targets, vol. 10, No. 8, pp. 892-898, (2011).
  • “Covalent Immobilization of Affinity Ligands”, ThermoFisher Scientific, found at www.thermofisher.com/us/en/home/life-science/protein-biology/protein-biology-learning-center/protein-biology-resource-library/pierce-protein-methods/covalent-immobilization-affinity-ligands.html, printed on Mar. 17, 2021.
  • Suurmond, J. et al., “Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity”, Journal of Clinical Investigation, vol. 125, No. 6, pp. 2194-2202, (2015).
  • Definition of “List of autoimmune diseases” printed from Wikipedia, the free encyclopedia on Mar. 17, 2021 found at https://en.wikipedia.org/wiki/List_of_autoimmune_diseases.
  • Liu, J. et al. “Rational design of “Turn-On” allosteric DNAzyme catalytic beacons for aqueous mercury ions with ultrahigh sensitivity and selectivity”, Angewandte Chemie International Edition, vol. 119, pp. 7731-7734, (2007).
  • Li, J. et al., “A highly sensitive and selective catalytic DNA biosensor for lead ions”, Journal of the American Chemical Society, vol. 122, No. 42, p. 10466-10467, (2000).
  • Qu, H. et al., “Rapid and label-free strategy to isolate aptamers for metal ions”, ACS Nano, vol. 10, No. 8, pp. 7558-7565, (2016).
  • Banks, M.L. et al., “Immunopharmacotherapies for treating opioid use disorder” Trends in Pharmacological Sciences, vol. 39, issue 11, pp. 908-911, (2018).
  • Rowley et al. “The role of pathogenic autoantibodies in autoimmunity” Antibodies, vol. 4, pp. 314-353, (2015).
  • Tullis, R.H. et al., “Affinity hemodialysis for antiviral therapy. I. removal of HIV-1 from cell culture supernatants, plasma, and blood”, Therapeutic Apheresis and Dialysis, vol. 6, No. 3, pp. 213-220, (2002).
  • Tullis, R.H. et al., “Affinity hemodialysis for antiviral therapy. II Removal of hiv-1 viral proteins from cell culture supernatants and whole blood”, Blood Purification, vol. 21, No. 1, pp. 58-63, (2003).
  • Marleau, A.M. et al., “Exosome removal as a therapeutic adjuvant in cancer”, Journal of Translational Medicine, Biomed Central, vol. 10, No. 1, pp. 1-12,(2012).
Patent History
Patent number: D952157
Type: Grant
Filed: Jun 19, 2020
Date of Patent: May 17, 2022
Assignee: Qualigen Inc. (Carlsbad, CA)
Inventor: Michael Poirier (Vista, CA)
Primary Examiner: Anhdao Doan
Application Number: 29/738,845
Classifications
Current U.S. Class: Hematological Or Intravenous Treatment (41) (D24/169)